Ekso Bionics Holdings, Inc. (EKSO)

Ekso Bionics Holdings, Inc. (EKSO) Healthcare & Pipeline Overview

Ekso Bionics Holdings, Inc. specializes in exoskeleton technology for medical rehabilitation and industrial augmentation, offering devices like EksoNR and EksoUE. The company operates globally, focusing on improving patient outcomes and worker productivity with its innovative wearable robotics, but faces challenges in profitability.

What Is the Investment Thesis for EKSO?

Ekso Bionics operates in a high-growth market for rehabilitation and human augmentation exoskeletons. Key value drivers include expanding applications of EksoNR in rehabilitation centers and increasing adoption of EksoWorks products in industrial settings. The company's gross margin of 52.9% indicates potential for profitability as sales scale. Upcoming catalysts include potential regulatory approvals for new medical applications and expansion of partnerships. However, the company's negative profit margin of -135.7% and reliance on external funding pose significant risks. Investors should monitor revenue growth, cost management, and progress towards profitability.

Based on FMP financials and quantitative analysis

EKSO Key Highlights

• Market Cap of $38.57M reflects its small-cap status and growth potential in the exoskeleton market.
• Gross Margin of 52.9% demonstrates strong pricing power and efficient production costs.
• Beta of 0.78 indicates lower volatility compared to the overall market, suggesting relative stability.
• Operates in two segments: EksoHealth and EksoWorks, diversifying its revenue streams across medical and industrial applications.
• Partnership with Lockheed Martin Corporation provides access to advanced technologies and expanded market opportunities.

Who Are EKSO's Competitors?

EKSO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are EKSO's Key Strengths?

• Innovative exoskeleton technology for medical and industrial applications.
• Established presence in the rehabilitation market with EksoNR.
• Strategic partnerships with Lockheed Martin and other industry leaders.
• Strong gross margin indicating pricing power.

What Are EKSO's Weaknesses?

• Negative profit margin and reliance on external funding.
• Limited market share compared to larger medical device companies.
• High R&D expenses and regulatory hurdles.
• Small employee base of 61 employees.

What Could Drive EKSO Stock Higher?

• Potential regulatory approvals for new medical applications of EksoNR.
• Expansion of partnerships with rehabilitation centers and industrial companies.
• Increasing adoption of exoskeletons in the workplace to reduce injuries.
• New product development and innovation in exoskeleton technology.

What Are the Key Risks for EKSO?

• Financial-distress signal — its Altman Z-Score of -19.13 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Negative profit margin and reliance on external funding.
• Competition from established medical device companies.
• Regulatory changes and reimbursement challenges.
• Economic downturns affecting healthcare spending.
• Technological obsolescence.

What Are the Growth Opportunities for EKSO?

• Expansion in Rehabilitation Centers: Ekso Bionics can increase its market penetration by targeting more rehabilitation centers with its EksoNR device. The market for rehabilitation robotics is projected to reach $1.8 billion by 2028, offering a substantial growth opportunity. By demonstrating the clinical benefits and cost-effectiveness of EksoNR, the company can drive adoption and generate recurring revenue through rentals and service contracts.
• Industrial Partnerships: The EksoWorks segment can leverage partnerships with industrial companies to deploy exoskeletons in manufacturing, construction, and logistics. The market for industrial exoskeletons is expected to reach $4.7 billion by 2030, driven by the need to reduce workplace injuries and improve productivity. Collaborating with industry leaders can provide access to large-scale deployments and valuable feedback for product development.
• Geographic Expansion: Ekso Bionics can expand its geographic footprint by entering new markets in Asia Pacific and Latin America. These regions offer significant growth potential due to increasing healthcare spending and rising awareness of exoskeleton technology. Establishing distribution networks and securing regulatory approvals in these markets will be crucial for successful expansion.
• New Product Development: Investing in R&D to develop new exoskeleton applications and improve existing products can drive long-term growth. The company can explore opportunities in areas such as geriatric care, sports medicine, and military applications. Innovation in sensor technology, AI algorithms, and wearable materials can enhance the performance and usability of exoskeletons.
• Telehealth Integration: Integrating telehealth capabilities into EksoNR can enable remote monitoring and therapy, expanding access to rehabilitation services. The telehealth market is growing rapidly, driven by the need for remote patient care and cost-effective healthcare solutions. By offering remote training and support, Ekso Bionics can differentiate itself from competitors and reach a wider patient population.

What Opportunities Does EKSO Have?

• Expansion into new geographic markets and applications.
• Increasing adoption of exoskeletons in industrial settings.
• Integration of AI and telehealth technologies.
• Growing demand for rehabilitation robotics.

What Threats Does EKSO Face?

• Competition from established medical device companies.
• Regulatory changes and reimbursement challenges.
• Economic downturns affecting healthcare spending.
• Technological obsolescence.

What Are EKSO's Competitive Advantages?

• Proprietary exoskeleton technology with patents protecting key innovations.
• Established brand reputation in the medical rehabilitation market.
• Strategic partnerships with leading hospitals and research institutions.
• First-mover advantage in specific exoskeleton applications.

What Does EKSO Do?

Ekso Bionics Holdings, Inc., founded in 2005 and headquartered in Richmond, California, designs, develops, sells, and rents exoskeleton products across the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates through two segments: EksoHealth and EksoWorks. The EksoHealth segment focuses on medical applications, designing, engineering, manufacturing, and marketing exoskeletons for rehabilitation. Their flagship product, EksoNR, is a wearable bionic suit used by physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury. EksoUE is an upper extremity assistive device that reduces the effect of gravity on the wearer's shoulders and arms. The EksoWorks segment caters to industrial applications, creating exoskeleton devices that allow able-bodied users to perform difficult, repetitive work for extended periods. Ekso Bionics has a license agreement with Lockheed Martin Corporation, enhancing its technological capabilities and market reach. The company's mission is to enhance human capabilities by pioneering the development of innovative exoskeleton solutions, addressing unmet needs in both healthcare and industrial sectors.

What Products and Services Does EKSO Offer?

• Designs and develops exoskeleton devices for medical rehabilitation and industrial use.
• Sells and rents exoskeleton products to hospitals, rehabilitation centers, and industrial companies.
• Provides the EksoNR, a wearable bionic suit for patients with brain, stroke, and spinal cord injuries.
• Offers the EksoUE, an upper extremity assistive device to reduce strain on shoulders and arms.
• Markets exoskeletons to able-bodied users in industrial settings to enhance physical capabilities.
• Enables physical therapists and physicians to treat patients with advanced rehabilitation technology.

How Does EKSO Make Money?

• Direct sales of exoskeleton devices to medical facilities and industrial clients.
• Rental programs for EksoNR and other products, providing recurring revenue.
• Service and maintenance contracts for installed exoskeletons.
• Licensing agreements for technology and intellectual property.

What Industry Does EKSO Operate In?

The medical instruments and supplies industry is experiencing growth driven by technological advancements and an aging population. The exoskeleton market, in particular, is expanding rapidly, fueled by increasing demand for rehabilitation solutions and workplace safety enhancements. Ekso Bionics competes with other companies in the robotics and medical device space, focusing on specialized exoskeleton applications. The industry is characterized by high regulatory hurdles and significant R&D investments. Market trends include the integration of AI and IoT technologies into medical devices to improve patient outcomes and operational efficiency.

Who Are EKSO's Key Customers?

• Hospitals and rehabilitation centers using EksoNR for patient therapy.
• Industrial companies deploying EksoWorks exoskeletons to improve worker safety and productivity.
• Physical therapists and physicians who utilize Ekso devices in their practice.
• Patients recovering from stroke, spinal cord injury, and other neurological conditions.

Company Profile

Ekso Bionics Holdings, Inc. operates in the Healthcare Equipment & Supplies industry within the Healthcare sector. It is headquartered in San Rafael, US. The company is led by CEO Scott G. Davis. EKSO has traded publicly since 2014.

How Ekso Bionics Holdings, Inc. Is Valued

Ekso Bionics Holdings, Inc. carries a market capitalization of $38.57M, placing it in the micro-cap category. Relative to its peer group, EKSO's quantitative score of 23/100 is below the peer average of 68/100.

Key Financial Metrics

Return on assets is -79.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -22.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.55 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -19.7%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Ekso Bionics Holdings, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -19.13 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Ekso Bionics Holdings, Inc. revenue of about $19.4M for fiscal 2026, with EPS near $-0.10.

Net buyingInsider Activity

Over the past six months, Ekso Bionics Holdings, Inc. insiders filed 12 SEC Form 4 transactions — 0 sales and 12 purchases. On net that is roughly 121K shares acquired (about $1.2M) — insiders putting money in tends to read as conviction.

EKSO Financials

EKSO Latest News

No recent news available for EKSO.

EKSO Analyst Consensus

EKSO MoonshotScore

EKSO Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources